BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD)…
Tag: Acadia
Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on…